ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
Authors:
- Paul G. KempsPKPaul G. Kemps
- Jennifer PicarsicJPJennifer Picarsic
- Benjamin H. DurhamBDBenjamin H. Durham
- Zofia Hélias-RodzewiczZHZofia Hélias-Rodzewicz
- Laura Hiemcke-JiwaLHLaura Hiemcke-Jiwa
- Cor van Den BosCBCor van Den Bos
- Carel J. M. van NoeselCNCarel J. M. van Noesel
- Jan A. M. van LaarJLJan A. M. van Laar
- Robert M. VerdijkRVRobert M. Verdijk
- Uta E. FluckeUFUta E. Flucke
- Pancras C. W. HogendoornPancras C. W. Hogendoorn
Top Cited Papers
Open Access
- 13 January 2022
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 139 (2) , 256-280
Abstract
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.Keywords
This publication has 79 references indexed in Scilit:
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutationBlood, 2013
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- Cyclin D as a therapeutic target in cancerNature Reviews Cancer, 2011
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancyBlood, 2008
- Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladderLaboratory Investigation, 2007
- Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936Leukemia, 2006
- Juvenile Xanthogranuloma in Childhood and AdolescenceAmerican Journal of Surgical Pathology, 2005
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936Leukemia, 2003